Methods and compositions relating to microbial treatment and diagnosis of disorders
Inventors
Cutcliffe, Colleen • Eid, John S. • Bullard, James H. • SCHICKLBERGER, Marcus F.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-10842831-B2
Publication Date
2020-11-24
Expiration Date
Abstract
The present disclosure provides methods, systems, compositions, and kits to address the need for microbiome-related treatment of health conditions and disease. The present disclosure provides for treatment of metabolic conditions using microbial compositions.
Core Innovation
The disclosure describes methods for producing a microbial composition suitable for human consumption. The method includes culturing Akkermansia muciniphila in a culture medium comprising substantially a plant-based culture medium, thereby generating cultured Akkermansia muciniphila.
The cultured Akkermansia muciniphila is formulated into a unit dosage form. The unit dosage form comprises the cultured Akkermansia muciniphila and a second microbe comprising a 16S rRNA sequence that comprises at least about 97% sequence identity to a 16S rRNA sequence of Eubacterium hallii, thereby producing the microbial composition suitable for human consumption.
Claims Coverage
1 independent claim is provided. The claim includes 2 core inventive elements: culturing Akkermansia muciniphila in a substantially plant-based culture medium and formulating a unit dosage form that includes a second microbe defined by a 16S rRNA identity relationship to Eubacterium hallii.
Plant-based culturing of Akkermansia muciniphila
Culturing Akkermansia muciniphila in a culture medium comprising substantially a plant-based culture medium, thereby generating cultured Akkermansia muciniphila.
Unit dosage formulation with 16S-defined second microbe
Formulating the cultured Akkermansia muciniphila into a unit dosage form comprising the cultured Akkermansia muciniphila and a second microbe comprising a 16S rRNA sequence with at least about 97% sequence identity to a 16S rRNA sequence of Eubacterium hallii.
The claim scope is centered on producing a human-consumable microbial composition by plant-based culturing of Akkermansia muciniphila and co-formulating a unit dosage form that further includes a second microbe defined by 16S rRNA sequence identity to Eubacterium hallii.
Stated Advantages
Documented Applications
No documented applications found
Interested in licensing this patent?